Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug MK-1200 tested in advanced cancer patients

NCT ID NCT06242691

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer esophageal cancer gastric cancer gastroesophageal cancer gastroesophageal junction adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

  • Beijing Cancer hospital-Digestive Oncology ( Site 0401)

    Beijing, Beijing Municipality, 100142, China

  • Bradfordhill-Clinical Area ( Site 0301)

    Santiago, Region M. de Santiago, 8420383, Chile

  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0415)

    Huai'an, Jiangsu, 223300, China

  • Fujian Cancer Hospital-oncology department ( Site 0409)

    Fuzhou, Fujian, 350000, China

  • Hadassah Medical Center ( Site 0604)

    Jerusalem, 9112001, Israel

  • Rabin Medical Center-Oncology ( Site 0603)

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus-Oncology Division ( Site 0602)

    Haifa, 3109601, Israel

  • START Midwest ( Site 0014)

    Grand Rapids, Michigan, 49546, United States

  • START Mountain Region ( Site 0015)

    West Valley City, Utah, 84119, United States

  • Samsung Medical Center-Division of Hematology/Oncology ( Site 1003)

    Seoul, 06351, South Korea

  • Sheba Medical Center ( Site 0605)

    Ramat Gan, 5265601, Israel

  • Sourasky Medical Center ( Site 0601)

    Tel Aviv, 6423906, Israel

  • South Texas Accelerated Research Therapeutics (START) ( Site 0005)

    San Antonio, Texas, 78229, United States

  • The Alfred Hospital ( Site 0103)

    Melbourne, Victoria, 3004, Australia

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004)

    Louisville, Kentucky, 40202, United States

  • University of Virginia Health System-Hematology-Oncology ( Site 0009)

    Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.